Patient-level digital twins expected to strengthen evidence generation in Phase1/2 clinical study evaluating VTx-002, a first-in-class vectorized antibody targeting TDP-43 pathology in patients with a ...
Background: Artificial intelligence technologies are being actively introduced in clinical practice. The most promising solutions are AI-assistants based on large language models (LLMs). Determining ...
BUFFALO, N.Y. — Karen Frank, MD, PhD, chief of the Department of Laboratory Medicine at the National Institutes of Health Clinical Center, has been appointed Peter A. Nickerson, PhD, Professor and ...
Pilates continues to dominate the fitness industry, according to a recent report. ClassPass, a wellness booking platform, released its 2025 Look Back Report on Dec. 9, and Pilates remains the top ...
In their recent paper ‘Is pregnancy a disease?’, Anna Smajdor and Joona Räsänen argue in the affirmative, highlighting features shared by both pregnancy and paradigmatic diseases. In particular, they ...
VectorY Therapeutics Receives FDA Clearance of IND to Proceed with the PIONEER-ALS Phase 1/2 Trial of VTx-002, a First-in-Class Vectorized Antibody Targeting TDP-43 Pathology in ALS VectorY ...
VectorY Therapeutics, a leader in vectorized antibody therapies for neurodegenerative diseases, announced today that the U.S. Food and Drug Administration (FDA) has cleared the company to proceed with ...
Amsterdam, The Netherlands, and Boston, MA — December 3, 2025— VectorY Therapeutics, a leader in vectorized antibody therapies for neurodegenerative diseases, announced today that the U.S. Food and ...
When native Coloradan Lexi Borger arrived at Dordt University, she knew that she wanted to work with children. Growing up in a family of ten kids—and helping younger siblings along the way—sparked her ...
In the most traditional definition of return-on-investment, Sam Terese, former CEO and president of Alverno Laboratories, would say that his company isn’t experiencing a strict apples-to-apples ...
Tempus AI has acquired the digital pathology developer Paige, including its FDA-cleared, artificial-intelligence-powered programs for spotting the signs of cancer. The deal totals $81.25 million, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results